Sitemap Contact Privacy Statement Imprint

Pharmacogenomics of Breast Cancer

The clinical outcomes of breast cancer patients have been significantly improved in recent years, yet many breast cancer patients experience cancer relapse or drug-induced toxicities. Adverse outcomes result from intrinsic tumor biology, treatment-induced resistance traits, as well as host factors such as impaired drug metabolism and endogenous ligands interfering with drug–target action. My research focuses on mitigating clinical resistance of hormone-receptor positive breast cancer treatment, which due to its high prevalence holds high chances to reduce overall death burden. This includes pharmacogenomic prediction of impaired drug exposure (e.g. due to genetic polymorphism or drug-target interactions), genome-wide searches of novel treatment-predictive features such as the immune response in hormone-sensitive tumors, tumor cell model research for estrogen-receptor signaling and linked resistance pathways, and the molecular profiling of breast tumors based on their transcriptome and somatic mutation landscape. Prediction tools such as liquid-biopsy based detection of circulating tumor markers and the employment of ex-vivo microtumor models (organoids) will be used to translate novel diagnostic markers and/or multimodal drug target approaches into the clinic.

 

Major Projects
  • Pharmacogenomics of breast cancer
  • Hormone-sensitive trial exploration for novel treatment predictors
  • Prospective study: supplementation of standard TAMoxifen with ENDOXifen
  • Estrogen receptor regulation and signaling
  • Early detection: Liquid biopsy in adjuvant settings, tumor profiling
Dr. Werner Schroth

phone: ++49-711-8101 3754

Selected References
Major Networks and Collaborations, Funding
  • International Tamoxifen Pharmcogenomics Consortium (ITPC)
  • Marie Curie Initial Training Network (ITN) „FightingDrugFailure: Priorities and Standards in Phamacogenomic Research: Opportunities for a Safer and More Efficient Pharmacotherapy“
  • Funded by German Research Council (DFG), German Federal Ministry of Education and Research (BMBF), Interfaculty Center for Pharmacogenomics and Drug Research (ICEPHA), Tübingen, Germany

Curriculum Vitae Werner Schroth, PhD

Affiliation
Scientist at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tübingen

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
Auerbachstr. 112
D-70376 Stuttgart
phone: ++49-711-8101 3754
fax: ++49-711-859295
email: werner.schroth@ikp-stuttgart.de
Education and Professional Career
1987-1994 Study of Biology, J.W.Goethe University, Frankfurt, Germany
1995 Diploma in Biology at J.W.Goethe University, Frankfurt, Germany: population genetics in sea turtles
1996 Environmental Research Award, J.W.Goethe University
1996-1998 Employment DFG project ‘microsatellites paternity analyses’, J.W.Goethe University
1997-2000 Dissertation at J.W.Goethe University, Frankfurt, Germany
1999-2000 Research Fellowship Deutsche Bundesstiftung Umwelt DBU
2000 PhD degree at J.W.Goethe University, Frankfurt, Germany: speciation and environmental monitoring in moon jellyfish
2001-2003 Post-doctoral position, ‘evolution of homeobox genes in lower metazoans’, Prof B. Schierwater, ITZ Hannover, Germany
2000-2003 Consultant & scientist-in-charge ‘autoimmune diagnostics’, Dermatological Institute, Prof P. Kind, Offenbach, Germany
2004 to present Scientist in oncology research ‘pharmacogenomics and molecular profiling of breast cancer’, Institute of Clinical Pharmacology, Prof. H. Brauch, IKP Stuttgart, Germany
Professional Memberships
Affiliate membership: American Association for Cancer Research AACR